Categories: Technology

BIO-key Receives Notice of Non-Compliance from Nasdaq Related to Delay of its Form 10-K Filing

HOLMDEL, N.J., April 22, 2026 (GLOBE NEWSWIRE) — BIO-key International, Inc. (Nasdaq: BKYI), a global leader in Identity and Access Management (IAM) and biometric authentication technologies, announced today that it has received a notification letter from The Nasdaq Stock Market, LLC informing the Company that it was not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission, due to the Company’s failure to timely file its Annual Report on Form 10-K for the year ended December 31, 2025. The Notification Letter has no immediate effect on the listing or trading of the Company’s common stock on the Nasdaq Capital Market.

BIO-key is working with its auditors to finalize its Form 10-K which it expects to file next week.

About BIO-key International, Inc. (www.BIO-key.com)

BIO-key is revolutionizing authentication and cybersecurity with biometric-centric, multi-factor identity and access management (IAM) software securing access for over forty million users. BIO-key allows customers to choose the right authentication factors for diverse use cases, including phoneless, tokenless, and passwordless biometric options. Its cloud hosted or on-premise PortalGuard IAM solution provides cost-effective, easy-to-deploy, convenient, and secure access to computers, information, applications, and high-value transactions.

Engage with BIO-key:

Facebook – Corporate: https://www.facebook.com/BIOkeyInternational/ 
LinkedIn – Corporate: https://www.linkedin.com/company/bio-key-international 
X – Corporate: @BIOkeyIntl
X – Investors: @BIO_keyIR
StockTwits: BIO_keyIR
   

Investor Contacts:
William Jones, David Collins
Catalyst IR
BKYI@catalyst-ir.com
212-924-9800

GlobeNews Wire

Recent Posts

Evaxion presents new preclinical data for cytomegalovirus vaccine program EVX-V1

The new data demonstrates the potential to improve control of acute infection, latency, and viral…

7 hours ago

Hemab Therapeutics Presents New Clinical Data from HMB-002 in Von Willebrand Disease and Introduces HMB-003 for Heavy Menstrual Bleeding at the ISTH 2026 Congress

July 12, 2026 06:28 ET  | Source: Hemab Therapeutics, Inc. HMB-002 clinical data demonstrate proof…

7 hours ago

FROM THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE 2026

FORMER ELITE SOCCER PLAYERS SHOWEVIDENCE OF BRAIN HEALTH CHANGES IN MID-LIFEKey TakeawaysNew research provides insights…

7 hours ago

GAC Group to Celebrate 30 Million Global Users on July 16

GUANGZHOU, China, July 12, 2026 /PRNewswire/ -- From the roll-off of its first vehicle to…

10 hours ago

What Separates Commercial Money Counters From Consumer Models?

MIAMI, FL, July 11, 2026 (GLOBE NEWSWIRE) -- To a first-time buyer, a consumer money…

20 hours ago